Eisai has been granted a patent for a therapeutic agent aimed at treating fatty liver diseases. The agent consists of a specific compound or its pharmaceutically acceptable salt, which is administered in a therapeutically effective amount. GlobalData’s report on Eisai gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eisai, Human telomerase RT biomarker was a key innovation area identified from patents. Eisai's grant share as of June 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic agent for treating fatty liver diseases
The granted patent US12023320B2 outlines a method for treating fatty liver disease through the administration of a specific compound, denoted by a designated formula. The claims specify that the treatment involves administering a therapeutically effective amount of this compound, which can also be in the form of a pharmaceutically acceptable salt, such as hydrochloride. The patent particularly addresses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), with further distinctions made regarding the presence of liver fibrosis and inflammation in these conditions.
The claims further elaborate on the administration routes for the compound, indicating that it can be delivered orally or parenterally. Specific claims highlight the treatment of NAFLD, including cases where the disease is accompanied by liver fibrosis or inflammation, as well as similar considerations for NASH. This patent provides a framework for potential therapeutic interventions targeting these liver diseases, emphasizing the importance of the compound's formulation and its effective delivery in managing these conditions.
To know more about GlobalData’s detailed insights on Eisai, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
